On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
FridaySep 25, 2020 2:41 pm

QualityStocksNewsBreaks – 180 Life Sciences Corp. Advancing Lead Program, Plans Additional Clinical Trials

180 Life Sciences, a clinical-stage biotechnology company, is dedicated to producing solutions designed to battle inflammation when the body’s natural processes go awry. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, designed to block the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases. The company is advancing on this front as discussed by a recent article that reads, “180 Life Sciences’ lead program is in phase 2b/3 clinical trials and expects to deliver its first results next year. Other clinical trials planned by the company are…

Continue Reading

FridaySep 25, 2020 2:18 pm

QualityStocksNewsBreaks – SRAX Inc.’s (NASDAQ: SRAX) Sequire Provides Key Insight for Public Company Execs

SRAX (NASDAQ: SRAX), a provider of digital-marketing and consumer data-management technology products, gives public companies an edge with critical data to successfully activate media campaigns, engage shareholders and attract investment. The company’s data analytics platform – Sequire – has proven a key tool for decision makers in the public realm, recently doubling its user base to amass over 1 million active investors and traders. A recent article discussing this quotes SRAX founder and CEO Christopher Miglino, who states, “We are creating a community of public company executives that are taking back their data. For too long these leaders have relied…

Continue Reading

FridaySep 25, 2020 2:07 pm

QualityStocksNewsBreaks – Cybin Corp. Leverages Two-Pronged Approach to Target Psychedelic, Nutraceutical Sectors

Cybin Corp., a Canada-based life-science company, looks to benefit from its growing footprint in two billion-dollar markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see significant growth in the coming years. The global nutraceutical market was valued at $382.51 billion in 2019 and is expected to grow at an 8.3% compound annual growth rate (“CAGR”) over the next seven years. Meanwhile, the psychedelic drugs market is projected to reach $6.85 billion by 2027. Cybin’s business model is structured around two wholly owned divisions focused on targeting both promising spaces. A recent article discussing this reads, “Cybin is committed…

Continue Reading

FridaySep 25, 2020 1:48 pm

QualityStocksNewsBreaks – Trxade Group Inc. (NASDAQ: MEDS) Shines Spotlight on Dynamic Platform Capabilities

Trxade Group (NASDAQ: MEDS), an integrated drug-procurement, delivery and health-care platform, recently had the opportunity to showcase its growing medical technology accomplishments at multiple virtual investor conferences. Trxade Group CEO Suren Ajjarapu took the company’s message well beyond physical borders to virtual summits in the month of September, providing insight into the dynamic capabilities and expansion of the Trxade Exchange platform. A recent article discussing this reads, “Trxade Group has been building its B2B platform into a B2C-friendly portfolio that helps independent local pharmacies compete with large-scale retail chains through drug pricing transparency and network strength. The platform also assists health…

Continue Reading

FridaySep 25, 2020 1:14 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is “One to Watch”

CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit. In preclinical studies, the company’s second drug candidate, a novel DNA binding agent, was 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Industry reports estimate that the global brain…

Continue Reading

FridaySep 25, 2020 12:35 pm

Pac Roots Cannabis Corp. (CSE: PACR) Leverages Expertise, Resources to Establish Dominant Position in Growing Cannabis Market

Legal marijuana market set to top more than $90 billion by 2027 Pac Roots places top priority on developing, delivering finest cannabis genetics Optimized farming systems employed in most fertile areas means maximum opportunity for harvest After experiencing a few roadblocks over the last year, the cannabis sector looks to be picking up speed. In fact, a recent Data Bridge Market Research study reports that the global legal marijuana market should top more than $90 billion by 2027 (https://ibn.fm/UE8Tj). Pac Roots Cannabis (CSE: PACR), a Canadian company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach, has taken…

Continue Reading

FridaySep 25, 2020 11:58 am

QualityStocksNewsBreaks – Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) Announces Pricing of $12.6M US IPO

Siyata Mobile (TSX.V: SIM) (OTCQX: SYATF) (FRA: WK3D) (NASDAQ: SYTA, SYTAW), a B2B global vendor of next-generation cellular solutions, today announced the pricing of its U.S. initial public offering (“IPO”) of 2,100,000 units at a price of US$6.00 per unit. According to the update, each unit consists of one common share and one warrant to purchase one common share. The common shares and warrants are immediately separable from the units and will be issued separately. Approved to list on the Nasdaq Capital Market, the common shares and warrants commenced trading on September 25, 2020, under the symbols “SYTA” and “SYTAW.”…

Continue Reading

FridaySep 25, 2020 11:48 am

180 Life Sciences Corp. Leading Research into Novel Drug Therapies Expected to Produce First Results of Phase 2b/3 Trial in 2021

Anti-inflammatory therapeutics market to generate revenues of $191.42 billion through 2027 Novel drug therapy for Fibrosis and Anti-TNF trials being conducted by Professor Sir Marc Feldmann, who already developed one of the most commonly used anti-TNF medications, Remicade The number of conditions with chronic inflammation is expected to increase persistently over the next 30 years in the United States. 180 Life Sciences is in the process of being acquired by KBLM Merger Corp. and the acquisition is expected to finalize in Q4 2020 Clinical-stage biotechnology company 180 Life Sciences Corp. is leading the way with research into the world’s most…

Continue Reading

FridaySep 25, 2020 11:27 am

QualityStocksNewsBreaks – Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF) Participates in Gravitas Clean Technology Investor Day, Announces Strategic Collaboration

Exro Technologies (CSE: XRO) (OTCQB: EXROF), a leading technology company that has developed a new class of power electronics for powertrains, recently announced its participation in the Gravitas Clean Technology Investor Day. According to the update, Exro CEO Sue Ozdemir presented at the event, which took place virtually on September 24, 2020, sharing the company’s growth strategy and fielding questions from investors. In addition, the company on Thursday announced its collaboration with Heinzmann GMBH & Co. KG to integrate Exro's patented coil drive technology into micro mobility applications. Heinzmann is a renowned manufacturer of electric drives up to 30 kW…

Continue Reading

FridaySep 25, 2020 10:58 am

The Movie Studio Inc. (MVES) Making Major Moves in Growing Streaming Market

Streaming sites are among businesses that have seen an uptick in sales during worldwide pandemic Content key for companies in streaming space The Movie Studio moving forward in space, expanding content and keeping costs down Not all businesses are struggling through the worldwide pandemic. A recent CompariTech article reported that streaming video is becoming a viable option for a growing number of viewers around the world, resulting in increasing numbers for companies involved in streaming content (https://ibn.fm/wSNni). The Movie Studio (MVES), a vertically integrated motion picture production and distribution company, is looking to become a major player in this star-studded…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.


Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered